Treatment of tumor necrosis factor-mediated diseases

Abstract

A method of treating and/or preventing a TNF-mediated disease in an individual is disclosed. Also disclosed is a composition comprising a tumor necrosis factor antagonist and a CD4+ T cell inhibiting agent. TNF-mediated diseases include rheumatoid arthritis; Crohn's disease, and acute and chronic immune diseases associated with transplantation.

1 .- 22 . (Canceled)  
     
     
         23 . A method for treating or preventing Crohn's disease in an individual in need thereof comprising administering to the individual cyclosporin or analog thereof in combination with a tumor necrosis factor antagonist, in therapeutically effective amounts.  
     
     
         24 . A method of  claim 23  wherein the tumor necrosis factor antagonist is an anti-tumor necrosis factor antibody or fragment thereof.  
     
     
         25 . A method of  claim 24  wherein the antibody is a chimeric antibody.  
     
     
         26 . A method of  claim 23  wherein the tumor necrosis factor antagonist is a receptor molecule which binds to tumor necrosis factor.  
     
     
         27 . A method of  claim 26  wherein the receptor molecule is a tumor necrosis factor receptor/immunoglobulin G fusion protein.  
     
     
         28 . A method of  claim 23  wherein the tumor necrosis factor antagonist prevents or inhibits tumor necrosis factor synthesis, tumor necrosis factor release or its action on target cells.  
     
     
         29 . A method of  claim 28  wherein the tumor necrosis factor antagonist is a phosphodiesterase inhibitor.  
     
     
         30 . A method of  claim 29  wherein the phosphodiesterase inhibitor is pentoxifylline.  
     
     
         31 .- 45 . (Canceled)